BENTLEY PHARMACEUTICALS INC Form 8-K March 08, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 8, 2005

Date of Report (Date of Earliest Event Reported)

BENTLEY PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-10581 (Commission File Number) 59-1513162

(I.R.S. Employer Identification No.)

Bentley Park
2 Holland Way
Exeter, New Hampshire
(Address of Principal Executive Offices)

03833 (Zip Code)

(603) 658-6100

(Registrant s Telephone Number, Including Area Code)

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 8-K

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

	ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 8-K

Item 2.02. Results of Operations and Financial Condition	Item 2.02.	Results of	Operations an	nd Financial	Condition.
--	------------	------------	---------------	--------------	------------

On March 8, 2005, Bentley Pharmaceuticals, Inc. issued a press release announcing financial results for the fourth quarter and year ended December 31, 2004. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

- (c) Exhibits
- 99.1 Earnings press release for the fourth quarter and year ended December 31, 2004 dated March 8, 2005. Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 8, 2005 By: /s/ Michael D. Price

Michael D. Price Vice President and Chief Financial Officer

2

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 8-K

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Earnings press release for the fourth quarter and year ended December 31, 2004 dated March 8, 2005
	3